Results 1 to 10 of about 33,520 (111)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions

Frontiers in Immunology, 2021
Acral and mucosal melanomas are extremely rare in Caucasians; however, they are the predominant melanoma subtypes in Asians and other non-Caucasian populations.
Lu Si, Jun Guo, Lili Mao
exaly   +3 more sources

Mucosal melanoma in 1481 patients in the Netherlands. An overview of metastatic patterns, main driver mutations and the efficacy of therapeutic strategies [PDF]

BJC Reports
Background Mucosal melanomas are a rare melanoma subtype with poor prognosis. This project aimed to identify the main driver mutations of the different mucosal melanomas and to evaluate the efficacy of targeted/immunotherapies in patients with metastatic
E. Jutten, S. Kruijff, M. H. M. Oonk, M. F. Lutke Holzik, B. L. van Leeuwen, K. P. Wevers   +5 more
doaj   +2 more sources

Cutaneous and mucosal melanoma among the Palestinian population: a retrospective clinicopathological study with comparative regional context [PDF]

BMC Cancer
Background Cutaneous and mucosal melanoma are biologically and clinically distinct malignancies whose epidemiology varies markedly across populations and skin phototypes.
Ibrahim Salhi, Sami Bannoura, Orgina Abedaljawwad, Zaidoun Salah   +3 more
doaj   +2 more sources

Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report [PDF]

Frontiers in Oncology
Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina.
Arnar B. Ingason, Venkatesa P. Muruganandam, Ikechukwu Chidobem, Jessica Cintolo-Gonzalez, Hibba tul Rehman   +4 more
doaj   +2 more sources

Sinonasal mucosal melanoma in an elderly patient: a case report [PDF]

Journal of Medical Case Reports
Background Mucosal melanoma is an aggressive Malignancy arising from melanocytes in mucosal membranes. Sinonasal mucosal melanoma accounts for approximately 1% of all melanomas and 4% of all sinonasal tumors.
Edwin Liwa, Gilbert Nkya, Angela Pallangyo, Patrick Amsi, Jeremia Pyuza, Furaha Kasyupa, Deardiana Gladstone, Alex Mremi, Sylvia Moshi, Glory Makupa, Jabu Mavundla, Stephen Gondwe, Evalily Mbwilo, Subira Matiku   +13 more
doaj   +2 more sources

Combatting mucosal melanoma: recent advances and future perspectives

Melanoma Management, 2018
Mucosal melanomas are a rare subtype of melanoma and are associated with a particularly poor prognosis. Due to the rarity of the diagnosis, and the pace with which the management of cutaneous melanoma has evolved over recent years, there is little good ...
Helen Tyrrell, Miranda Payne
exaly   +3 more sources

Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine [PDF]

Frontiers in Immunology
BackgroundMucosal melanomas arise from melanocytes in mucosal tissues, and it’s usually detected at a late stage owing to its anatomic location. Advances in immunotherapies have proved to be promising therapeutic approaches for advanced mucosal melanoma ...
Yong Zhang, Ting Wang, An-Qi Lyu, Fang Zhang, Fang-Hui Li, Ling-Di Zhao, Zi-Bing Wang, Yi-Man Shang, Bao-Zhen Ma, Xiao-Qun Dong, Quan-Li Gao   +10 more
doaj   +2 more sources

Case Report: Surgery combined with targeted therapy for metastatic anorectal malignant mucosal melanoma [PDF]

Frontiers in Oncology
BackgroundAnorectal mucosal melanoma is a rare tumor with a poor prognosis. Timely diagnosis and treatment are essential for improving patient survival. Currently, there is no standardized treatment approach for this disease.
Yadong Yao, Yadong Yao, Pule Liu, Pule Liu, Kai Liu, Lirong Lian, Lirong Lian, Shuo Gao, Shuo Gao   +8 more
doaj   +2 more sources

Case Report: Trastuzumab deruxtecan plus toripalimab in ERBB2-amplified cervical mucosal melanoma [PDF]

Frontiers in Oncology
Cervical mucosal melanoma is a rare, aggressive malignancy with poor prognosis due to delayed diagnosis and limited treatment efficacy. Current therapies, including immune checkpoint inhibitors (e.g., anti-PD-1 agents), chemotherapy, and targeted ...
Xiao-Xia Wang, Min-Xin Wang, Chao Sui
doaj   +2 more sources

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

Cancer Medicine, 2021
Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB).
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie‐Hurder, F. Stephen Hodi   +13 more
doaj   +1 more source